News
PGEN
1.395
-0.36%
-0.005
*Correct: Actym Therapeutics, Not AnaptysBio, Appoints Thomas Smart as CEO
Dow Jones · 4h ago
*AnaptysBio Names Thomas Smart as CEO >ANAB
Dow Jones · 4h ago
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO of a new drug modality to treat solid tumors. Mr. Smart has 25 years of experience in senior management and executive roles across the biopharmaceutical industry. Actym's lead candidate, ACTM-838, will enter clinical evaluation later this year.
Dow Jones · 4h ago
Weekly Report: what happened at PGEN last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at PGEN last week (0408-0412)?
Weekly Report · 04/15 09:23
Weekly Report: what happened at PGEN last week (0401-0405)?
Weekly Report · 04/08 09:25
AquaBounty Technologies Inc reports results for the quarter ended in December - Earnings Summary
AquaBounty Technologies Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.19 per share. Revenue rose 22.8% to $554.00 thousand from the same quarter last year. Wall Street expected the company to report a profit of $1.53 per share in the quarter.
Reuters · 04/02 14:21
Weekly Report: what happened at PGEN last week (0325-0329)?
Weekly Report · 04/01 09:24
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
TipRanks · 03/26 12:10
Weekly Report: what happened at PGEN last week (0318-0322)?
Weekly Report · 03/25 09:25
Precigen Cut to Underweight From Neutral by JP Morgan
Dow Jones · 03/22 16:22
JP Morgan Downgrades Precigen to Underweight
Benzinga · 03/22 16:12
J.P. Morgan cuts Precigen to underweight, cites burn rate
J.P. Morgan cuts Precigen to underweight, cites burn rate. The investment bank says it has doubts about the company's ability to continue as a going concern. The company has a burn rate of around $20M per quarter and $63M in cash and equivalents.
Seeking Alpha · 03/22 15:10
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
FactSet Research Systems Inc. Shares dipped 5.2% to $462.36 on Thursday. The company reported worse-than-expected second-quarter revenue and issued FY24 guidance. Other stocks moving in the mid-day session include Bioscience, Inc. And Kaival Brands Innovations Group.
Benzinga · 03/21 18:39
Precigen’s Financial Tightrope: Balancing R&D Investment and Funding Challenges Amid Economic Headwinds
TipRanks · 03/21 06:02
Precigen Price Target Maintained With a $14.00/Share by JMP Securities
Dow Jones · 03/20 13:51
JMP Securities Reiterates Market Outperform on Precigen, Maintains $14 Price Target
Benzinga · 03/20 13:40
Precigen Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/20 11:02
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target
Benzinga · 03/20 10:52
Buy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial Stability
TipRanks · 03/20 10:17
More
Webull provides a variety of real-time PGEN stock news. You can receive the latest news about Precigen Inc through multiple platforms. This information may help you make smarter investment decisions.
About PGEN
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.